Furthermore, Bozec et al. investigated combined mTOR (temsirolimus) and EGFR (cetuximab) targeting in an orthotopic xenograft model of HNSCC, which culminated in synergistic effects against tumour growth [62]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.